is a R&D; company focused on developing therapeutics to address neurological disabilities resulting from excess inhibition of the brain. Balance's pharmacological approach, based on technology licensed from Stanford University has demonstrated promising potential to address cognitive deficits in animal models of Down syndrome and Alzheimer's disease. Clinical trials for the company's lead product are currently in progress for Down Syndrome. Balance Therapeutics is located in San Bruno, CA and has a wholly owned subsidiary in Melbourne, Australia.